Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)

About the company

Hepion Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.

Sector

Health Technology

Industry

Pharmaceuticals: Other

Employees

12

$NoneM

Total Revenue

12

Employees

$5.68M

Market Capitalization

-0.48

Price/Earning ratio

Stock price

Gross Margin (in %)

Total gross margin

Operating Margin (in %)

Total operating margin

Net Margin (in %)

Total net margin

Dividend Yield (in %)

Dividend per share

$0

Industry peers

Name Ticker Market capitalization (in USD Million) Revenues (in USD Million) Price/Book Price/Earning Net margin (in %)
Horizon Therapeutics Plc HZNP 11600.40 1376.00 4.95 18.29 43.06
Catalent, Inc. CTLT 10838.26 2872.00 5.44 103.91 3.63
Perrigo Co. Plc PRGO 7561.03 4837.00 1.30 51.58 3.02
Bausch Health Cos., Inc. BHC 6474.02 8597.00 9.03 -3.42 -21.96
Jazz Pharmaceuticals Plc JAZZ 6255.75 2188.00 2.16 22.86 12.81
United Therapeutics Corp. UTHR 5174.19 1443.00 1.80 9.99 36.59
MyoKardia, Inc. MYOK 4329.06 34.00 12.58 -13.96 -201.73
Axsome Therapeutics, Inc. AXSM 2833.95 None 19.23 -31.51 None
ArQule, Inc. ARQL 2240.00 5.00 15.75 -55.56 -808.06
SAGE Therapeutics, Inc. SAGE 2236.52 9.00 2.63 -3.45 -413.06
Pacira Biosciences, Inc. PCRX 2199.54 435.00 5.90 -5237.00 -0.02
Corcept Therapeutics, Inc. CORT 2095.96 335.00 4.81 19.75 31.64
Prestige Consumer Healthcare, Inc. PBH 1844.67 963.00 1.55 13.01 14.77
Revolution Medicines, Inc. RVMD 1829.59 48.00 4.75 -25.84 -146.29
Madrigal Pharmaceuticals, Inc. MDGL 1673.70 0.00 4.47 -16.38 -624.74
Ironwood Pharmaceuticals, Inc. IRWD 1598.26 440.00 -22.62 18.85 19.14
Innoviva, Inc. INVA 1580.87 285.00 3.74 8.18 66.41
Intercept Pharmaceuticals, Inc. ICPT 1506.88 272.00 -44.85 -4.39 -127.53
Portola Pharmaceuticals, Inc. PTLA 1329.78 121.00 19.53 -4.77 -232.73
Zogenix, Inc. ZGNX 1313.55 5.00 3.59 -3.09 -241.62
Supernus Pharmaceuticals, Inc. SUPN 1274.94 402.00 2.02 10.93 28.90
Revance Therapeutics, Inc. RVNC 1181.11 0.00 4.66 -6.33 41.82
Theravance Biopharma, Inc. TBPH 1169.64 88.00 -8.21 -4.74 -280.80
Amphastar Pharmaceuticals, Inc. AMPH 1074.08 327.00 2.68 21.08 15.90
Endo International Plc ENDP 795.72 3014.00 -1.09 -2.84 -9.09
BellRing Brands, Inc. BRBR 766.74 954.00 -0.42 5.82 13.98
Eagle Pharmaceuticals, Inc. EGRX 678.44 192.00 3.65 269.22 1.29
Assembly Biosciences, Inc. ASMB 672.22 16.00 3.01 -6.76 -601.75
Aerie Pharmaceuticals, Inc. AERI 642.62 79.00 5.10 -3.18 -252.92
Collegium Pharmaceutical, Inc. COLL 593.64 299.00 4.25 -45.95 -4.21
Anika Therapeutics, Inc. ANIK 537.18 125.00 1.86 19.38 22.73
Catalyst Pharmaceuticals, Inc. CPRX 514.67 119.00 5.01 11.73 36.09
Intersect ENT, Inc. XENT 439.36 102.00 4.15 -8.80 -48.61
BioDelivery Sciences International, Inc. BDSI 408.48 130.00 5.84 -55.50 -5.01
ANI Pharmaceuticals, Inc. ANIP 370.68 203.00 1.90 -237.62 -0.67
Albireo Pharma, Inc. ALBO 337.35 11.00 3.43 -4.41 -730.55
MEI Pharma, Inc. MEIP 289.67 5.00 4.99 -7.43 -539.48
Mallinckrodt Plc MNK 204.12 3037.00 0.11 -0.17 -39.56
Agile Therapeutics, Inc. AGRX 166.97 None 2.72 -8.09 None
Marinus Pharmaceuticals, Inc. MRNS 160.02 0.00 6.20 -2.37 None
Zynerba Pharmaceuticals, Inc. ZYNE 144.90 0.00 2.38 -4.04 -699.94
Cerecor, Inc. CERC 118.22 7.00 7.56 -5.24 -429.22
Ampio Pharmaceuticals, Inc. AMPE 94.38 1.00 66.00 -5.08 None
AcelRx Pharmaceuticals, Inc. ACRX 91.20 2.00 -1.68 -1.63 -644.25
Evoke Pharma, Inc. EVOK 84.96 None 29.50 -12.64 None
Adamas Pharmaceuticals, Inc. ADMS 71.68 57.00 -4.57 -0.77 -160.44
CTI BioPharma Corp. CTIC 69.62 3.00 3.11 -1.69 -111.83
Aclaris Therapeutics, Inc. ACRS 67.65 4.00 1.19 -0.49 None
Oramed Pharmaceuticals, Inc. ORMP 63.36 3.00 5.10 -4.96 -464.15
Cassava Sciences, Inc. SAVA 54.34 41.00 2.86 -11.92 76.71
SCYNEXIS, Inc. SCYX 48.89 0.00 10.27 -1.26 -30.84
Cumberland Pharmaceuticals, Inc. CPIX 48.60 47.00 0.99 -10.80 -9.59
Natural Alternatives International, Inc. NAII 48.58 114.00 0.67 -12.85 -3.19
IsoRay, Inc. ISR 37.52 9.00 7.00 -11.20 -36.08
Lipocine, Inc. LPCN 36.90 0.00 8.79 -2.46 None
Acasti Pharma, Inc. ACST 35.84 827.00 2.33 -0.58 -7.45
Neos Therapeutics, Inc. NEOS 34.45 65.00 -2.65 -1.97 -26.74
PLx Pharma, Inc. PLXP 27.99 0.00 -2.68 -2.96 119.04
CytRx Corp. CYTR 22.11 0.00 1.60 -3.19 408.46
EyeGate Pharmaceuticals, Inc. EYEG 19.00 3.00 2.36 -1.60 -264.21
Regulus Therapeutics, Inc. RGLS 14.49 0.00 1.28 -0.68 -272.13
Tetraphase Pharmaceuticals, Inc. TTPH 12.30 8.00 0.65 -0.15 -798.18
Intec Pharma Ltd. NTEC 10.43 None 1.34 -0.24 None
VIVUS, Inc. VVUS 8.69 73.00 -0.19 -0.29 -39.28
Sonoma Pharmaceuticals, Inc. SNOA 6.74 19.00 1.07 -2.16 -25.58
KemPharm, Inc. KMPH 6.02 15.00 -0.17 -0.35 -120.48
Hepion Pharmaceuticals, Inc. HEPA 5.68 None 1.77 -0.48 None
Tonix Pharmaceuticals Holding Corp. TNXP 4.20 None 1.05 -0.09 None
Ritter Pharmaceuticals, Inc. RTTR 0.45 None 0.17 -0.03 None

Latest insider transactions

Date Role Name Transaction Quantity Quantity Owned After

Hepion Pharmaceuticals Announces Advancement to Final Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431

5d ago, source: YAHOO!

EDISON, NJ / ACCESSWIRE / June 29, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease ...

Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals' CRV431 Demonstrates Efficacy in Kidney Fibrosis

12d ago, source: Finanznachrichten

Results Support CRV431's Potential to More Broadly Treat Fibrotic Diseases EDISON, NJ / ACCESSWIRE / June 22, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) ("Hepion" or the "Company"), a biopharma ...

After Market Hours: Hepion Pharma, Apyx Medical, Ideanomics Rise; IVERIC, Spirit Aerosystems Slip

12d ago, source: Nasdaq

Shares of the biopharmaceutical company, which focuses on the development of pleiotropic drug therapy for the treatment of ...

Hepion Pharmaceuticals: CRV431 Continues To Progress In Early Phase NASH Clinical Trials

Opinion ago, source: Seeking Alpha

Hepion's drug, CRV431, has demonstrated safety and tolerability in Phase 1 clinical studies. It is now entering Phase 2a for NASH, which represents a $10 billio ...

17 Healthcare Stocks Moving In Tuesday's Pre-Market Session

11d ago, source: MSN

Apyx Medical, Inc. (NASDAQ:APYX) stock rose 31.80% to $6.30. The most recent rating by JMP Securities, on May 12, is at Market Outperform, with a price target of $5. • Hepion Pharmaceuticals ...

Hepion Pharmaceuticals' CRV431 Demonstrates Efficacy in Kidney Fibrosis

12d ago, source: YAHOO!

A third group of eight mice, the Sham group, did not undergo surgery and did not receive drug treatment. The fibrotic scarring in response to the UUO procedure was visualized by Sirius red staining of ...

After Market Hours: Hepion Pharma, Apyx Medical, Ideanomics Rise; IVERIC, Spirit Aerosystems Slip

12d ago, source: Business Insider

Disclaimer | Commerce Policy | Made In NYC | Stock quotes by finanzen.net (RTTNews) - Hepion Pharmaceuticals, Inc. (HEPA) - Shares of the biopharmaceutical company, which focuses on the ...



Portfolio items

Follow companies to create your optimal portfolio.
or
Refresh this page to see your newly added stocks.